Skip to content

The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection

A Randomized, Parallel-group, Placebo Control, Non-inferiority Trial to Investigate the Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04595786
Acronym
STAMP
Enrollment
228
Registered
2020-10-22
Start date
2020-10-30
Completion date
2024-07-11
Last updated
2025-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningioma, Seizures

Keywords

meningioma, blood management

Brief summary

Growing evidence of Tranexamic Acid (TXA) being used to reduce blood loss and blood transfusions in various guidelines. However, the adverse effects of TXA especially seizure has always been a problem of concern, especially in neurosurgery. Therefore, this study aims to provide a scientific evidence for the safety of TXA in supratentorial meningiomas resection patients.

Interventions

DRUGTranexamic acid

20mg/kg TXA was prepared in a 50ml syringe for intravenous pump

DRUG0.9% saline

0.9% saline was prepared in a 50ml syringe for intravenous pump

Sponsors

Beijing Tiantan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 1\) age 18-80 years * 2\) American Society of Anesthesiologist (ASA) classification score I\ III

Exclusion criteria

* 1\) allergic to tranexamic acid * 2\) preoperative seizures * 3\) history of thrombotic disease * 4\) chronic kidney disease * 5\) breastfeeding or pregnancy * 6\) refuse to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Early postoperative seizures within 7 daysWithin 7 days after surgeryPostoperative seizures were defined as a transient occurrence of involuntary movements, abnormal sensory phenomena, or an altered mental status that could not otherwise be explained.

Secondary

MeasureTime frameDescription
The changes in haemoglobin concentrationsDuring surgeryThe changes in haemoglobin concentrations between baseline and end of surgery.
The incidence of non-epileptic complicationsWithin 7 days after the interventionIncluding intracranial hematoma, deep vein thrombosis, pulmonary embolism, cerebral venous sinus thrombosis, stroke, myocardial infarction, acute kidney infarction, anaemia, and infection.
Estimated intraoperative blood lossDuring surgeryEstimated intraoperative blood loss = collected blood volume in the suction canister (ml) - volume of flushing (ml) + volume from gauze tampon (ml).
The intraoperative blood transfusion volume and rateDuring surgeryThe intraoperative blood transfusion volume and rate.
The intraoperative cell saver volume and rateDuring surgeryThe intraoperative cell saver volume and rate.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026